With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to ...

Evommune is set to make its stock market debut next week, but the biotech company is keeping investors guessing about its final share price.

At OCTSC, an expert discussed the biotech funding environment, market trends and for all key stakeholders in the healthcare space.

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

Medline named multi-year preferred supplier deals, international expansion and takeovers as ways it will drive further growth ...

We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...

Austrian biotech VALANX Biotech has appointed Klaus Orlinger as chief scientific officer, reinforcing its leadership as the ...

Pollon Life, a Chinese biotech company backed by Jack Ma’s Yunfeng Capital, has confidentially filed for a Hong Kong IPO that could raise about USD 300 million. The firm, maker of China’s first ...

New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative ...

Women leaders are driving success in life sciences but remain underrepresented and undervalued. That needs to change, writes ...

Sergey Brin’s name doesn’t appear in MapLight Therapeutics’ filings to go public, but the Google co-founder’s philanthropic ambitions are getting a big boost from the biotech’s market debut. His ...

The China Securities Regulatory Commission (CSRC) issued new guidelines to reform the offline IPO placement mechanism, giving ...